FGFR3 Antagonist for Skeletal Disorders Treatment

The USPTO published patent application US20260091033A1 for an FGFR3 antagonist for treating skeletal disorders linked to abnormal FGFR3 activation. The application, filed by inventors LEGEAI-MALLET, MUNNICH, BUSCA, and BARBAULT on January 15, 2025, covers compositions and methods for treatment. This publication represents a new patent application and creates no immediate compliance obligations for industry.

Amorphous Solid Dispersions Patent - Intra-Cellular Therapies

USPTO published patent application US20260091032A1 by Intra-Cellular Therapies, Inc. for stable amorphous solid dispersions of a quinoxaline-derived compound with potential applications in neurological and metabolic disorders. The application, filed August 6, 2025, contains 29 CPC classifications spanning formulations, compounds, and therapeutic indications.

CGRP Receptor Antagonists for Treating Chemotherapy-Induced Nausea and Vomiting

The USPTO published patent application US20260091031A1 by inventor Alberto Chiarugi covering a method of using CGRP receptor antagonists (gepants) for treating chemotherapy-induced nausea and vomiting (CINV). The application claims the use of these migraine-approved drugs to target CGRP neuropeptides to prevent and counteract drug-induced nausea including CINV.

HIGH-DOSE NALOXONE FORMULATION

The USPTO published patent application US20260091030A1 for high-dose Naloxone formulations designed to treat ultra-potent synthetic opioid overdose. Invented by Gita Shankar and Suresh Potharaju, the formulation comprises naloxone hydrochloride with preservatives, buffering agents, and tonicity modifiers. The application was filed September 1, 2023, and published April 2, 2026.

Pridopidine for ALS Treatment

USPTO published patent application US20260091028A1 by Prilenia Neurotherapeutics Ltd. for a method of treating amyotrophic lateral sclerosis (ALS) using pridopidine. The application claims therapeutic use of pridopidine or a pharmaceutically acceptable salt for human subjects afflicted with ALS. Application No. 19391284 was filed on 2025-11-17.

Stilbene Derivatives as AHR Regulators with Improved Photostability

The USPTO published patent application US20260091027A1 for stilbene derivatives serving as aryl hydrocarbon receptor (AHR) regulators with improved photostability over the marketed drug Benvitimod. The application, filed September 19, 2023 under Application No. 19113670, covers compounds of formula I-1, their stereoisomers, salts, and prodrugs, along with preparation methods for gram-to-kilogram scale synthesis.

Methods of Treating Inflammatory Diseases with Formula I and II Compounds

The USPTO published patent application US20260091026A1 covering compounds of Formula (I) and Formula (II), and their use in treating inflammatory diseases. The application was filed December 5, 2025, and published April 2, 2026, naming inventors Robert Joseph Moreau, Naomi S. Rajapaksa, David C. Tully, and others. The claimed subject matter includes novel compounds, pharmaceutical compositions, and methods of treatment for inflammatory diseases and disorders.

Markers for the Diagnosis of Biochemical Recurrence in Prostate Cancer

USPTO published patent application US20260092922A1 for biomarkers and diagnostic methods related to prostate cancer biochemical recurrence (BCR). The application (No. 19207308, filed May 13, 2025) includes 9 inventors and covers methods for detecting BCR biomarkers, compositions, and diagnostic kits. This is a routine patent publication with no new regulatory requirements.

Electroacupuncture vs Sham for Recurrent Lower UTI Prevention in Women

ClinicalTrials.gov registered a randomized controlled trial (NCT07507851) comparing electroacupuncture to sham treatment for prevention of recurrent lower urinary tract infections in women. The single-center trial is conducted as an RCT design. No compliance obligations are created by this registration.

Methylprednisolone Evaluation in Hepatic Surgery

ClinicalTrials.gov registered a new clinical trial (NCT07507643) evaluating methylprednisolone administration in patients undergoing liver surgery (hepatectomy). The randomized controlled study aims to assess perioperative outcomes including liver function recovery and inflammatory response. Healthcare institutions conducting hepatic surgery research are the primary affected parties.